Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus CYPROHEPTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus CYPROHEPTADINE HYDROCHLORIDE.
ACTIDIL vs CYPROHEPTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Category C
Category A/B
Antihistamine
Antihistamine